Dedicated to Pet Dog Heart Disease Interventional Treatment, ‘Hongyu Medical’ Completes 30 Million Series A Financing
March 27th reported
Recently, LeiYun.com learned that pet dog heart disease interventional treatment service provider 'Hongyu Medical' announced the completion of a RMB 300 million Series A financing, led by China CITIC Industrial Fund, followed by Lizhe Fund investment.
According to reports, this round of financing will be used to expand the global business of Hongyu's pet dog bicuspid valve interventional devices.
Hongyu Medical is committed to global pet dog heart disease interventional treatment, as the first company worldwide dedicated to the research and development of pet dog heart interventions, filling the gap in global pet dog cardiac treatment devices. Currently, it is cooperating with multiple top universities and veterinary hospitals globally, has entered clinical application stages in over 30 developed countries including the US, UK, France, Germany, and Japan, and is expected to achieve scale sales in the second half of the year.
Bicuspid valve regurgitation is very common in elderly small dogs, with a prevalence of 20-30%. In the United States alone, there are about 7.18 million dogs with bicuspid valve regurgitation. The prevalence increases with age. Bicuspid valve insufficiency can cause characteristic symptoms such as nocturnal cough, nocturnal wheezing, weakness, exercise intolerance, or fatigue after excitement, prolonged recovery time, cyanosis of the tongue, and even syncope. Dogs with severe bicuspid valve regurgitation have a survival period of only 3-6 months.
Traditional drugs have general effect, only relieving symptoms and cannot cure, the condition will continue to worsen. Monthly medication costs range from RMB 2000-4000. Or adopt open-chest surgery. Surgery is difficult and high-risk, with a high mortality rate, and the price of surgery is expensive, currently only a few teams globally complete individual cases, unable to large-scale promotion.
Hongyu V-CLAMP micro-invasive surgery is safe, has small trauma, and quick recovery, does not require heart stoppage, and body perfusion, with a cut of 2-3cm in the anterior cardiac area to deliver the device to repair the bicuspid valve, reducing bicuspid valve regurgitation, provides a new technical solution for the treatment of bicuspid valve regurgitation in pet dogs. The technology is jointly developed by Shanghai Han Yu Medical and Fudan University affiliated Zhongshan Hospital's Professor Ge Dunbo team, has achieved great success in human medicine field with nearly 100 clinical surgeries,
Globally, an estimated 30 million dogs have bicuspid valve regurgitation, urgently in need of treatment. Overseas product price is USD 1.2 million/set. Hongyu Medical is about to open a billion-level blue ocean market. In 2020, a building with a total area of over 20,000 square meters will soon commence construction.
30001.2/2020
